Algorae Raises $4M to Scale Commercial Sales and AI Drug Discovery Platform
Algorae raises $3.9 million to fuel commercial and R&D growth
Algorae Pharmaceuticals has raised $3,988,183 (before costs) through a combination of listed option exercises and a shortfall placement to sophisticated, long-term shareholders. The capital raise comprises 242,998,655 shares issued from the exercise of 1AIO listed options between November 2025 and March 2026, plus 89,350,001 placement shares priced at $0.012 (1.2 cents) per share.
The placement price represents a 25% discount to the last traded price of $0.016 and a 30.64% discount to the 5-day volume weighted average price of $0.0173. Net proceeds are earmarked to strengthen the Company’s working capital position as it scales its commercial portfolio under AlgoraeRx and advances its R&D pipeline under AlgoraeOS.
The completion of this capital raising significantly bolsters Algorae’s balance sheet ahead of planned commercial and pipeline expansion across both core business pillars.
Pro forma cash position strengthens runway
Following completion of the raise, Algorae holds a pro forma cash balance of approximately $5,560,000. This sits alongside a $3,000,000 receivables-based debt facility with ScotPac, announced on 21 January 2026.
The combined liquidity provides operational flexibility as the Company executes on near-term commercial opportunities and progresses scientific development initiatives.
When big ASX news breaks, our subscribers know first
What is a receivables-based debt facility?
A receivables-based debt facility allows a company to borrow against unpaid customer invoices (accounts receivable). Rather than waiting for customers to settle invoices, the business can access cash immediately by using those future payments as collateral. The lender typically advances a percentage of the invoice value, and the loan is repaid once the customer pays.
This financing structure is particularly suited to commercialisation-stage businesses generating recurring pharmaceutical sales. It provides non-dilutive working capital that scales naturally with revenue growth, meaning the facility becomes more valuable as sales expand. For Algorae, this demonstrates progression beyond pure equity funding to a stage where commercial receivables can underpin debt capacity.
Capital allocation: AlgoraeRx and AlgoraeOS
Algorae operates a dual business model spanning commercial pharmaceutical supply and AI-enabled drug discovery. AlgoraeRx, the commercial arm, sources, licences and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. AlgoraeOS, the Company’s proprietary AI platform, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design across an evolving R&D pipeline.
The capital raise supports both revenue generation through AlgoraeRx and scientific development via AlgoraeOS.
| Business Pillar | Focus |
|---|---|
| AlgoraeRx | Commercial pharmaceutical supply across Australia and New Zealand |
| AlgoraeOS | AI-enabled drug-combination discovery and preclinical R&D |
The allocation allows Algorae to fund near-term commercial growth whilst maintaining optionality on longer-term R&D upside driven by its AI platform.
The next major ASX story will hit our subscribers first
What’s next for Algorae?
Management has stated it will provide further updates as commercial and scientific initiatives progress. The strengthened balance sheet positions the Company to capitalise on momentum generated over recent months.
Potential near-term focus areas include:
- Scale AlgoraeRx commercial portfolio
- Advance AlgoraeOS R&D pipeline
- Leverage ScotPac facility as receivables grow
Investors will be watching for commercial contract announcements from AlgoraeRx and pipeline progress updates from AlgoraeOS as indicators of execution against the dual business strategy. The $3.9 million raise from existing long-term shareholders signals confidence in the Company’s ability to deliver on both fronts.
Want the Next Biotech Breakout in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX biotech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving announcements hit the ASX.